Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00741819 · ClinicalTrials.gov registry record · Phase 4
Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects
A Phase 4 study, sponsored by United Therapeutics.
- Completed
- Registry status
- Phase 4
- Development phase
- 73
- Enrollment target
NCT00741819 is a Phase 4 study that has completed, run by United Therapeutics. The registered enrollment target is 73 participants.
The verdict
NCT00741819, a Phase 4 study, has completed, sponsored by United Therapeutics.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 73 participants
- Enrollment target
Study Summary
This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis). Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, Week 6, Week 12, and Months 6, 12, 18 and 24 following initiation of treprostinil sodium.
Interventions
- DRUG Inhaled treprostinil
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 73 participants |
| Start Date | 2008-09 |
| Est. Completion | 2010-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00741819
The ClinicalTrials.gov registry entry for NCT00741819 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 73 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is United Therapeutics, which has 63 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Inhaled treprostinil is the first listed.
NCT00741819 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00741819 about?
NCT00741819 is a clinical study titled "Safety Evaluation of Inhaled Treprostinil Administration Following Transition From Inhaled Ventavis in Pulmonary Arterial Hypertension (PAH) Subjects". This is a 24-month, multi-center, prospective, open-label, safety evaluation in PAH subjects following transition from a stable dose of inhaled iloprost (Ventavis). Subjects are to be evaluated for safety throughout the course of the study while secondary assessments will be conducted at Baseline, ...
What is the current status of trial NCT00741819?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 73 participants. The study started on 2008-09. Estimated completion is 2010-12.
What interventions are being tested in trial NCT00741819?
The interventions under investigation include: Inhaled treprostinil (DRUG).
Who is sponsoring clinical trial NCT00741819?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.